Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:48:41.527Z.
Calculation as of: 2026-10-06T19:48:41.527Z.
Quote observation: 2026-10-06T19:45:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PEG RATIO
N/A
Obsidian Therapeutics Inc.
Market Cap
$13.84M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $13.84M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.99M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $14.25M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.11M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.30M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.12M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.88M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.82M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
